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SpO2/FiO2 as a predictor of high 
flow nasal cannula outcomes 
in children with acute hypoxemic 
respiratory failure
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The high-flow nasal cannula (HFNC) is a useful treatment modality for acute hypoxemic respiratory 
failure (AHRF) in children. We compared the ability of the oxygen saturation to fraction of inspired 
oxygen ratio (S/F) and arterial oxygen partial pressure to fraction of inspired oxygen ratio (P/F) to 
predict HFNC outcomes in children with AHRF. This study included children treated with HFNC due to 
AHRF from April 2013 to March 2019 at the Severance Children’s Hospital. HFNC failure was defined 
as the need for mechanical ventilation. Trends of S/F and P/F during HFNC were analyzed. To predict 
HFNC outcomes, a nomogram was constructed based on predictive factors. A total of 139 patients 
with arterial blood gas data were included in the S/F and P/F analyses. S/F < 230 at initiation showed 
high prediction accuracy for HFNC failure (area under the receiver operating characteristic curve: 
0.751). Univariate analyses identified S/F < 230 at HFNC initiation and < 200 at 2 h (odds ratio [OR] 
12.83, 95% CI 5.06–35.84), and hemato-oncologic disease (OR 3.79, 95% CI 1.12–12.78) as significant 
predictive factors of HFNC failure. The constructed nomogram had a highly predictive performance, 
with a concordance index of 0.765 and 0.831 for the exploratory and validation groups, respectively. 
S/F may be used as a predictor of HFNC outcomes. Our nomogram with S/F for HFNC failure within 2 h 
may prevent delayed intubation in children with AHRF.
Abbreviations
AHRF  Acute hypoxemic respiratory failure
ARDS  Acute respiratory distress syndrome
AUC  Area under the curve
CI  Confidence interval
HFNC  High flow nasal cannula
HR  Heart rate
MV  Mechanical ventilation
NIV  Noninvasive ventilation
OR  Odds ratio
P/F  Arterial oxygen partial pressure to fraction of inspired oxygen ratio  (PaO2/FiO2)
ROC  Receiver operating characteristic
ROX  Ratio of  SpO2/FiO2 to RR index
RR  Respiratory rate
S/F  Oxygen saturation to fraction of inspired oxygen ratio  (SpO2)/FiO2
High flow nasal cannula (HFNC) treatment has been described as a safe and useful technique to deliver heated 
and humidified oxygen to patients with acute hypoxemic respiratory failure (AHRF)1. The reported beneficial 
effects of HFNC include a decrease in physiological dead space, an improvement in oxygenation, and a reduction 
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in dyspnea by supplying oxygen at a high flow rate. As such, it may be used as a next-step respiratory support 
after nasal prongs or an oxygen mask in patients with respiratory  failure2,3. It has been reported that the admin-
istration of HFNC is associated with a reduction in the rate of intubation with mechanical ventilation (MV) in 
patients with  AHRF2. On the other hand, HFNC in infants with bronchiolitis did not decrease in an intubation 
group compared with a standard oxygen therapy group in a recent randomized  trial4. In any case, if respiratory 
symptoms, signs, or laboratory findings, including blood gas, do not improve after implementation of HFNC, a 
more aggressive ventilation technique, such as  noninvasive5 or invasive MV, should be considered. Identifying 
which patients may respond to HFNC and who may need MV can be a challenging  decision3. The decision to 
initiate MV is a critical one, as delayed intubation has proven to be a concern during HFNC  treatment3. Therefore, 
predicting the outcome of HFNC at an optimal time is crucial.
To date, improvements in gas exchange and respiratory rates (RRs) have reportedly remained a predictor of 
successful HFNC  outcomes6,7. In contrast, clinical parameters that warrant a subsequent need for intubation 
include absence of oxygenation improvement, absence of significant decrease in RR, presence of additional 
organ failure, or persistence of thoraco-abdominal  asynchrony7,8. The ratio of arterial oxygen partial pressure 
and fraction of inspired oxygen  (PaO2/FiO2; P/F) has been suggested as an outcome predictor for noninvasive 
ventilation in patients with  AHRF9. However, P/F requires arterial blood gas sampling; this procedure is invasive 
and not readily available in clinical practice, especially for  children10. The oxygen saturation  (SpO2)/FiO2 (S/F) 
ratio is a noninvasive, easily detectable, and readily available parameter that may be used as a surrogate marker 
for P/F in  children10–12. Furthermore, low S/F has been reported in cases of severe  AHRF13.
The prediction of HFNC outcomes may help clinicians make a timely and optimal decision to intubate 
children with AHRF. Given that P/F may predict HFNC outcomes, we sought to identify whether S/F could 
predict HFNC outcomes as well. We also aimed to construct a nomogram as a shortcut prediction tool for 
HFNC outcomes.
Methods
Patients. A retrospective chart review of children treated with HFNC due to AHRF was conducted at the 
Severance Children’s Hospital, a single tertiary center, between April 2013 and March 2019. All patients who 
received HFNC treatment for AHRF were included in the study. Exclusion criteria were age > 18 years, indica-
tion for endotracheal intubation within 1  h of HFNC initiation, post-extubation state, and congenital heart 
 disease14,15. Patients were divided into two groups: HFNC success and HFNC failure. HFNC failure was defined 
as the need for invasive MV due to progressive respiratory failure; the intubation decisions were based on the 
following criteria: a clinical deterioration such as tachypnea, chest retraction in respiratory status, a lack of 
improvement in signs of high respiratory muscle workload, or deterioration of the blood gas analysis, hemo-
dynamic instability, and deterioration of neurological  status2. HFNC success was defined as an improvement of 
respiratory distress with HFNC. A total of 419 children were treated using HFNC during the aforementioned 
period. Among these, 165 patients were excluded for the following reasons: 47 patients needed endotracheal 
intubation within 1 h of HFNC initiation, 52 patients were in the post-extubation state, 60 patients had congeni-
tal heart disease, and 6 patients were treated with noninvasive ventilation (NIV) due to progressive respiratory 
failure. Among the remaining 254 children, 139 who had available arterial blood gas data during the HFNC 
treatment were assigned to the exploratory group, and 114 without arterial blood gas data were included in 
the validation group. The Institutional Review Board of Severance Hospital approved this study (Seoul, Korea, 
Institutional Review Board 4-2020-0036) and granted the exemption of informed consent. Our study conformed 
to the Declaration of Helsinki, and all methods were performed following relevant guidelines and regulations.
Variable measurements and definitions. Demographic data such as age, sex, weight, underlying condi-
tion, and etiology of respiratory failure were recorded. Physiologic clinical variables such as the  SpO2,  FiO2, RR, 
heart rate (HR), and the flow rate of gas delivered (L/min) were also obtained at HFNC initiation. The P/F was 
obtained from the arterial blood gas analysis at the time of HFNC initiation.
To estimate oxygenation, we calculated the S/F as a noninvasive alternative to the P/F11. The  SpO2 and  FiO2 
were recorded at 1, 2, 4, and 12 h after HFNC initiation, and the corresponding series of S/F were calculated. 
HFNC initiation was defined as the point of the when HFNC treatment was started.
We evaluated the S/F as either a continuous or categorical variable, based on whether the patients achieved 
the therapeutic goal of S/F >  20016. The continuous S/F variable was substituted for the new categorical form to 
construct a nomogram model.
Device description and management. HFNC was implemented using the Optiflow (Fisher & Paykel 
Healthcare, Auckland, New Zealand) device, which comprises an air mixing device, a heated humidifier, a 
heated gas humidification chamber (MR290), a high-performance breathing circuit (900PT561), and a unique 
wide bore nasal cannula. The HFNC settings were determined by each attending physician.
Statistical analyses. The patients’ characteristics are summarized using numbers and percentages for cat-
egorical variables, and medians (interquartile range) for continuous variables. For intergroup comparisons, the 
Mann–Whitney U test was used for continuous variables, and the chi-squared test or Fisher’s exact test was used 
for categorical variables.
Receiver operating characteristic (ROC) curve analyses were performed to assess the S/F and P/F cutoff for 
HFNC outcomes. The area under the ROC curve (AUC was calculated as a measure of predictive capacity. The 
difference of AUC was determined using Delong’s  method17.
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Univariate logistic regression analysis was used to identify independent predictive risk factors for HFNC 
outcomes. Factors with a P value < 0.05 in the univariate analyses were included in the prediction model. The 
effect of each potential risk factor was denoted by the odds ratio (OR) and its 95% confidence interval (CI).
A nomogram was constructed based on selected predictive factors identified using the multivariate logistic 
regression model of the exploratory group data. The goodness of fit for each nomogram was verified using the 
Hosmer–Lemshow test. The discrimination ability of the nomogram was analyzed using the AUC. A calibration 
curve was generated to assess the discriminative performance and predictive accuracy of the nomogram. The pro-
posed prediction model was verified through external validation of the independent data. Statistical analyses were 
performed using Statistical Package for the Social Sciences version 25 and R (version 3.6.1, The R Foundation 
for Statistical Computing, Vienna, Austria). A two-sided P value < 0.05 was considered statistically significant.
Results
General characteristics. A total of 139 children with AHRF were included in the exploratory cohort. Base-
line characteristics of the study population are presented in Table 1. Fifty-nine (42.4%) patients who required 
intubation with MV were categorized as the HFNC failure group. The median time of HFNC treatment was 
14.1  h (interquartile range, 4.5–17.9), and 50 (83%) patients were intubated within 24  h. The leading cause 
for AHRF was pneumonia, which accounted for 67% of the total cases. Other etiologies for AHRF were bron-
chiolitis, bronchospasm, and acute respiratory distress syndrome (ARDS). HFNC success was statistically sig-
nificant in children with bronchiolitis (P = 0.041) and marginally significant in children with bronchospasm. 
However, HFNC treatment did not show any statistical significance in AHRF due to other etiologies. The most 
frequent underlying diseases associated with AHRF were neuromuscular disease (61.1%) and respiratory disease 
(12.2%); 17 children did not have any underlying disease. Patients with underlying hemato-oncologic diseases 
with AHRF frequently needed intubation with MV after HFNC treatment (P = 0.021).
The validation cohort comprised 114 patients. No significant differences were found between the exploratory 
and validation groups. The results in the validation group were consistent with those in the exploratory group, and 
S/F was significantly lower in the HNFC failure group (P < 0.001). The patients with hemato-oncologic disease 
frequently needed MV in the validation group (P = 0.039) (Supplementary Table S1).
Respiratory variables and serial S/F monitoring during HFNC. Table 2 shows the respiratory vari-
ables at initiation and serial S/F monitoring between the HFNC success and failure groups during HFNC treat-
ment. The  SpO2 at HFNC initiation was significantly lower in the HFNC failure group than in the HFNC success 
group (P < 0.001). Patients in the HFNC failure group were treated with higher  FiO2 at initiation compared with 
the patients in the HFNC success group (P = 0.001). Signs of respiratory distress such as RR and HR at HFNC 
initiation did not significantly differ between the two groups.
The P/F at initiation in the HFNC failure group was significantly lower than that in the HFNC success group 
(P = 0.004). We confirmed that S/F was positively correlated with P/F, which showed a linear relationship using 
the regression equation (S/F at initiation = 135.199 + 0.375 × P/F at initiation, P < 0.001, Supplementary Figure S1). 
Therefore, S/F was recorded as a respiratory oxygenation variable through serial monitoring. The serial S/F dis-
played significant differences between the groups during HFNC treatment (P < 0.001). The mean S/F profile plot 
over time based on a linear mixed model is shown in Supplementary Figure S2. The S/F of patients in the HFNC 
success group improved consistently during the initial 12 h after HFNC treatment. In the HFNC failure group, 
Table 1.  Patient characteristics in the exploratory group. Data are expressed as n (%) or medians (interquartile 
ranges). n, numbers; HFNC, high flow nasal cannula; ARDS, acute respiratory distress syndrome;  FiO2, 
fraction of inspired oxygen;  SpO2, pulse oximetry oxygen saturation; P/F,  PaO2/FiO2. a Others include systemic 
lupus erythematosus (three patients), metabolic disorder (two patients), and chronic kidney disorder (two 
patients).
Characteristics
HFNC success HFNC failure
P-value(n = 80) (n = 59)
Age, years 3.9 (1.2, 9.3) 6.0 (1.69, 13.7) 0.087
Male, n (%) 51 (63.7) 32 (53.3) 0.214
Cause of respiratory failure
Pneumonia (n = 94) 51 (63.7) 43 (72.9) 0.255
Bronchiolitis (n = 16) 13 (16.3) 3 (5.1) 0.041
Bronchospasm (n = 9) 8 (10.0) 1 (1.7) 0.078
ARDS (n = 9) 3 (3.8) 6 (10.2) 0.169
Upper airway disease (n = 3) 1 (1.3) 2 (3.4) 0.574
Underlying disease
Neuromuscular disease (n = 84) 48 (60.0) 36 (61.0) 0.904
Pulmonary disease (n = 17) 12 (15.0) 5 (8.5) 0.246
Hemato-oncology (n = 14) 4 (5) 10 (16.9) 0.021
Others (n = 7)a 3 (3.8) 4 (6.8) 0.419
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the S/F fluctuated within the first 4 h after HFNC initiation, with a minimum value of 197.72 (185.4–209.9) at 
2 h. However, when analyzing the difference in the S/F ratio over time, the amount of change in the S/F ratio was 
not a meaningful variable as a predictor of HFNC failure (Supplementary Table S2).
The AUC of S/F at initiation for predicting HFNC failure was 0.759, and the optimal cutoff was 230 (Fig. 1). 
The S/F < 230 showed 78.0% sensitivity and 68.7% specificity. The AUC for P/F at HNFC initiation was 0.643, 
and a cutoff < 195 showed 54.2% sensitivity and 81.2% specificity for predicting HFNC failure. The prediction 
power of S/F was observed to be better than that of P/F (P = 0.005).
Univariate logistic regression analysis of predictor of HFNC. Predictive potential risk factors for 
HFNC failure were identified using univariate logistic regression analyses in the exploratory group. The fol-
lowing variables were included in the analysis: RR, HR, flow/weight of HFNC setting at initiation, underlying 
disease, and newly categorized variables using an S/F < 230 at HNFC initiation and < 200 at 2 h (Table 3), which 
was identified based on the result of an analysis using various S/F cutoffs (Supplementary Table S3). A combina-
tion of S/F < 230 at HNFC initiation and S/F < 200 at 2 h (OR 13.067; 95% CI 5.06–35.84, P < 0.001), and hemato-
oncologic disease (OR 3.799; 95% CI 1.129–12.78, P = 0.031) were significantly associated with HFNC failure. 
Therefore, we chose these two variables (combination of S/F < 230 at initiation and < 200 at 2 h), and the presence 
of hemato-oncologic disease for multiple logistic regression analysis to construct a nomogram.
Table 2.  Respiratory variables and serial S/F monitoring between HFNC success and failure groups during 
HFNC. Data are expressed as n (%) or medians (interquartile ranges). n, numbers; HFNC, high flow nasal 
cannula;  FiO2, fraction of inspired oxygen;  SpO2, pulse oximetry oxygen saturation; P/F,  PaO2/FiO2; S/F,  SpO2/
FiO2.
HFNC success HFNC failure
P-value(n = 80) (n = 59)
Respiratory rate 35 (27.5, 42.5) 29 (24.7, 40.7) 0.424
Heart rate 152 (125.5, 163.0) 153.0 (137, 167.7) 0.077
HFNC setting at initiation
FiO2 0.4 (0.3, 0.5) 0.45 (0.38, 0.6) 0.001
Flow/weight 1.0 (0.8, 1.3) 1.0 (0.6, 1.4) 0.503
SpO2 at initiation 97.0 (95.0, 99.0) 89.0 (86.2, 92.7)  < 0.001
P/F at initiation 263.6 (213.4, 340.0) 191.7 (143.5, 286.5) 0.004
S/F
Initiation (n = 139) 242.5 (200.0, 320.0) 202.5 (153.3, 229.3)  < 0.001
1 h (n = 139) 243.7 (200.0, 306.4) 214.1 (161.8, 236.8)  < 0.001
2 h (n = 136) 247.5 (226.2, 323.3) 196.0 (153.9, 246.2)  < 0.001
4 h (n = 126) 250.0 (283.1, 326.7) 221.1 (168.5, 270.7)  < 0.001
12 h (n = 102) 250.0 (212.4, 330.0) 212.4 (146.4, 245.6)  < 0.001
Figure 1.  Comparison of receiver operating characteristic curve of P/F and S/F for predicting HFNC failure. 
The AUC was 0.653 for P/F at initiation and 0.759 for S/F at initiation. The difference between the AUCs was 
statistically significant (P = 0.005 by Delong’s method). P/F, ratio of arterial oxygen partial pressure to fraction of 
inspired oxygen  (PaO2/FiO2); S/F, ratio of oxygen saturation to fraction of inspired oxygen  (SpO2)/FiO2; AUC, 
area under the curve; HFNC, high flow nasal cannula.
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Nomogram construction and validation with HFNC. Figure 2a shows a nomogram that was con-
structed according to two independent predictors from the multiple logistic regression analysis. The Hosmer–
Lemshow test showed that the fit for multiple logistic regression model was good (P > 0.9999). In the exploratory 
group, the ROC curve according to the predicted probability of the multiple logistic regression analysis is shown 
in Fig. 2b, and the AUC was 0.765 (95% CI, 0.687–0.844). The calibration curve showed that the model was close 
Table 3.  Univariate analysis of predictive factors for HFNC failure. Data are expressed as odds ratios with 
95% confidence intervals. HFNC, high flow nasal cannula; S/F:  SpO2/FiO2. a Therapeutic goal: S/F ≥ 200 after 
initiation of HFNC.
Odds ratio 95% CI P-value
Respiratory rate 0.988 0.959–1.018 0.424
Heart rate 1.013 0.998–1.026 0.055
Flow/weight of HFNC setting 1.055 0.597–1.862 0.8541
Achievement of therapeutic goala of S/F
S/F at initiation ≥ 230 and S/F at 2 h < 200 1 [ref]
S/F at initiation < 230 and S/F at 2 h ≥ 200 3.967 1.286–8.136 0.002
S/F at initiation < 230 and S/F at 2 h < 200 13.067 5.06–35.84  < 0.001
Underlying disease
Neuromuscular disease 1.072 0.540–2.130 0.841
Pulmonary disease 0.515 0.171–1.551 0.384
Hemato-oncology 3.799 1.129–12.78 0.031
Figure 2.  Constructed nomogram and performance of the model in the training cohort for predicting HFNC 
outcomes. (a) Nomogram according to clinical indices for predicting HFNC outcomes. The nomogram is used 
by adding up points identified on the points scale for each variable. The points of the three predictors should be 
added to calculate the total points. The straight edge should be aligned to the “total points,” and the predicted 
value would be visible on the last line. (b) ROC curve of the nomogram in predicting HFNC failure in the 
training cohort. AUC shows the ability of the nomogram. (c) Calibration curve of nomogram in the training 
cohort. The x-axis is the predicted probability from the nomogram, and the y-axis is the actual probability. The 
dashed line represents performance of the ideal nomogram (predicted outcome perfectly corresponds with 
actual outcome). The dotted line represents the apparent accuracy of our nomogram without correction. The 
solid line represents bootstrap-corrected performance of our nomogram. AUC, area under the ROC curve; 
ROC, receiver operating characteristic; HFNC, high flow nasal cannula.
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to ideal (Fig. 2c). A higher score calculated in the nomogram was associated with a higher likelihood of HFNC 
failure. For example, a patient with a hemato-oncologic disease whose S/F was 190 initially and 210 at 2 h would 
achieve a total score of 90, which corresponded to an approximately 70% HFNC failure risk.
The nomogram also displayed its accuracy in the validation group, with an AUC = 0.831 (95% CI, 0.728–0.933) 
(Fig. 3a). The calibration curve presented an optimal agreement between the predicted and actual probabilities 
in the validation group (Fig. 3b).
Discussion
Our study showed that S/F, a noninvasive continuous monitoring variable, might be a good predictor for HFNC 
outcomes in children with AHRF. We created a nomogram for HFNC failure using S/F as a variable at initia-
tion and 2 h after HFNC implementation, as well as for the presence of hemato-oncologic disease, as a shortcut 
prediction tool.
Multiple studies have shown that S/F has a good correlation with P/F in patients with respiratory  failure11,12. 
Our study showed similarly consistent results with a good correlation between S/F and P/F. Furthermore, we 
showed that S/F had a better predictive power for HFNC failure compared with that of P/F. The best predictive S/F 
cutoff at initiation of HFNC was 230 in our study, which was higher than that in a previous study that reported 
S/F < 195 during the first hour of treatment to be associated with HFNC  failure18. The aforementioned study 
included patients with cardiac comorbidity, while we excluded children with congenital heart diseases because 
they have distinct S/F levels due to their underlying diseases.
We acknowledge that our inclusion criteria might have led to different S/F cutoff levels for the prediction of 
HFNC failure. Fine-tuning of S/F cutoff is essential to achieve an excellent prediction power for HFNC failure. 
Accordingly, we used a previously reported therapeutic goal of S/F and combined it with our initial S/F cutoff to 
create a categorical  variable16. Finally, an S/F cutoff of < 230 at initiation and < 200 at 2 h was observed to have a 
remarkable prediction power (OR, 13.067; 95% CI 5.06–35.84). An emerging issue for HFNC implementation 
in patients with AHRF is the concern of delayed intubation, which might worsen the clinical  deterioration19,20. 
Therefore, timely and appropriate identification of HFNC failure is crucial.
Several indices such as P/F and S/F have been reported to be predictors for HFNC  outcome16,21. The respira-
tory rate oxygenation (ROX) index, the ratio of  SpO2/FiO2 to RR, has recently been proposed to be a better 
predictor for HFNC failure compared with that of S/F alone in  adults3,22. Moreover, the heart rate, acidosis, 
consciousness, oxygenation, and respiratory rate (HACOR) score has been suggested as a predictive tool for 
noninvasive ventilation (NIV) failure in  adults23. We also evaluated vital sign changes over time, including 
changes in HR and RR, although they did not differ between the HFNC success and failure groups (Supplemen-
tary Table S4). However, these indices using actual respiratory variables are difficult to apply directly in children 
with AHRF due to the variability of RR with age in  children24. Therefore, our categorical S/F variable may help 
clinicians decide within 2 h whether the next step respiratory support, including noninvasive or invasive MV, 
should be performed.
Our study showed that the presence of an underlying hemato-oncologic disease was independently associated 
with HFNC failure, suggesting the deleterious effect of such a disease on HFNC outcome. Our findings support 
Figure 3.  Validation of nomogram for predicting HFNC outcomes in patients with AHRF. (a) ROC curve 
of the nomogram with 114 patients in the validation cohort. (b) Calibration plot of the nomogram in the 
validation cohort. The black line indicates logistic calibration of the validation cohort. The x-axis is the predicted 
probability from nomogram, and the y-axis is the actual probability. The dashed line represents performance of 
the ideal nomogram (predicted outcome perfectly corresponds with actual outcome). ROC, receiver operating 
characteristic; HFNC, high flow nasal cannula; AHRF, acute hypoxemic respiratory failure.
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those of a previous study that reported that HFNC neither improved discomfort nor decreased the need for intu-
bation in patients with hemato-oncologic  diseases25. In our study, 70% of patients with hemato-oncologic diseases 
in the HFNC failure group had a severe AHRF with a P/F of 150 mmHg at HFNC initiation, and pneumonia was 
the cause of AHRF in all patients with hemato-oncologic diseases. This result parallels that of a previous study, 
which showed that the etiology of AHRF (pneumonia, OR 11.2) was a significant risk factor for HFNC  failure26. 
HFNC failure in children with hemato-oncologic diseases might lead to various clinical conditions, complica-
tions, and problems unrelated to  AHRF27. Further, the conditions associated with the hemato-oncologic diseases 
might not be influenced by the mode of oxygen  delivery25. Moreover, supporting evidence has shown that the 
time needed to improve oxygenation during AHRF might be longer in patients with hemato-oncologic diseases 
than in other  patients28. These findings may explain why the presence of underlying hemato-oncologic disease 
was identified as an independent parameter for HFNC failure in our study data. As such, HFNC in patients with 
hemato-oncologic diseases and AHRF should be monitored with more caution.
Our study is the first to build a nomogram that predicts HFNC failure in children with AHRF. With the help 
of our nomogram, which was constructed using a combination of time-series S/F and hemato-oncologic disease 
as predictors, clinicians may estimate the individual probability of HFNC outcome in a patient without the need 
for an invasive examination. The nomogram, based on time-series S/F at initiation and at 2 h, can guide the next 
respiratory support, including intubation in children with AHRF regardless of their etiologies. Furthermore, 
we included both internal and external validation procedures, which demonstrated strong discrimination and 
calibration. With the ability to estimate individual risk in an easy to use and straightforward manner, we believe 
that our nomogram has an advantage over simple predictors.
Our results should be interpreted with caution, as six patients who required escalation to other NIVs were 
not assessed. NIV was actively implemented during the middle of the study period; consequently, those patients 
were excluded to maintain the homogeneity of the study. We also acknowledge the inclusion of measurements 
in the analysis that were performed with > 97%  SpO2, where the oxyhemoglobin dissociation curves might 
have been unchanged. However, some children with AHRF who receive appropriate oxygen therapy have an 
 SpO2 > 97%29. Real-world clinical evidence in children with AHRF is necessary, and it can reasonably include 
patients with > 97%  SpO2 to reflect current practice. A good correlation between S/F and P/F using data with 
S/F > 97% has been also demonstrated, which is consistent with our  results30. Third,  FiO2 based on the liter flow 
with the HFNC could potentially be overestimated due to entrainment of room air, especially when the HFNC 
flow rate is lower than the patient’s inspiratory flow rate. Therefore, we applied the flow  rates3–5,31 from 0.5 to 2.0 
L/kg/min up to a maximum of 30 L/min to prevent these problems. Fourth, this study was retrospective with 
inevitable limitations such as lack of data in the medical record, provider-dependent decision for intubation 
even though the physicians followed the institutional protocols, and uneven age distribution between the HFNC 
success and failure groups despite not reaching statistical significance. Lastly, we acknowledge that the validation 
cohort had a lower HFNC failure rate and higher S/F ratio compared with that of the exploratory cohort, even 
though both groups had a comparable composition of underlying disease and proportion of causative disease. 
Thus, the constructed nomogram needs to be validated in another independent cohort, including children with 
severe AHRF.
In conclusion, S/F may be an easy-to-use predictor of HFNC outcomes in children with AHRF. We con-
structed a nomogram using S/F for HFNC failure within 2 h, which may prevent delayed intubation in children 
with AHRF.
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